Search Results Search Sort by RelevanceMost Recent Case and Commentary Dec 2006 Relief Organizations with Counseling Restrictions Robert D. Orr, MD Virtual Mentor. 2006;8(12):814-817. doi: 10.1001/virtualmentor.2006.8.12.ccas3-0612. Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 1 Hasan Shanawani, MD, MPH Virtual Mentor. 2005;7(7):469-473. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507. Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 2 Kathleen Nathan Lowe, MSW, ACSW, CMSW Virtual Mentor. 2005;7(7):473-475. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507. Case and Commentary Oct 2005 Too Much Information? Commentary 1 Christopher Kodama, MD Virtual Mentor. 2005;7(10):652-655. doi: 10.1001/virtualmentor.2005.7.10.ccas2-0510. Case and Commentary Oct 2005 Too Much Information? Commentary 2 Kathryn M. Conniff and Ligia Peralta, MD Virtual Mentor. 2005;7(10):655-659. doi: 10.1001/virtualmentor.2005.7.10.ccas2-0510. Case and Commentary Oct 2005 Universal Precautions Leslie E. Wolf, JD, MPH Virtual Mentor. 2005;7(10):670-673. doi: 10.1001/virtualmentor.2005.7.10.ccas3-0510. Case and Commentary Jun 2016 Prescribing “Off-Label”: What Should a Physician Disclose? Katrina Furey, MD and Kirsten Wilkins, MD Off-label prescribing of drugs is appropriate when their use is in the patient’s best interest on the basis of credible, published scientific data. AMA J Ethics. 2016;18(6):587-593. doi: 10.1001/journalofethics.2016.18.6.ecas3-1606. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page Next › Last page Last »
Case and Commentary Dec 2006 Relief Organizations with Counseling Restrictions Robert D. Orr, MD Virtual Mentor. 2006;8(12):814-817. doi: 10.1001/virtualmentor.2006.8.12.ccas3-0612.
Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 1 Hasan Shanawani, MD, MPH Virtual Mentor. 2005;7(7):469-473. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507.
Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 2 Kathleen Nathan Lowe, MSW, ACSW, CMSW Virtual Mentor. 2005;7(7):473-475. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507.
Case and Commentary Oct 2005 Too Much Information? Commentary 1 Christopher Kodama, MD Virtual Mentor. 2005;7(10):652-655. doi: 10.1001/virtualmentor.2005.7.10.ccas2-0510.
Case and Commentary Oct 2005 Too Much Information? Commentary 2 Kathryn M. Conniff and Ligia Peralta, MD Virtual Mentor. 2005;7(10):655-659. doi: 10.1001/virtualmentor.2005.7.10.ccas2-0510.
Case and Commentary Oct 2005 Universal Precautions Leslie E. Wolf, JD, MPH Virtual Mentor. 2005;7(10):670-673. doi: 10.1001/virtualmentor.2005.7.10.ccas3-0510.
Case and Commentary Jun 2016 Prescribing “Off-Label”: What Should a Physician Disclose? Katrina Furey, MD and Kirsten Wilkins, MD Off-label prescribing of drugs is appropriate when their use is in the patient’s best interest on the basis of credible, published scientific data. AMA J Ethics. 2016;18(6):587-593. doi: 10.1001/journalofethics.2016.18.6.ecas3-1606.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.